Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin by Keishiro Fukumoto et al.
RESEARCH ARTICLE Open Access
Lymphovascular invasion status at
transurethral resection of bladder tumors
may predict subsequent poor response of
T1 tumors to bacillus Calmette-Guérin
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Abstract
Background: Lymphovascular invasion (LVI) is an important step in the process of tumor dissemination and
metastasis outside the primary organ, but the relationship between LVI and the prognosis of T1 non-muscle
invasive bladder cancer (NMIBC) has not been fully evaluated. Accordingly, the present study was performed to
evaluate whether LVI had an impact on the clinical outcome in patients with T1 NMIBC.
Methods: A total of 116 consecutive patients were diagnosed with T1 NMIBC from 1994 to 2013 at Keio University
Hospital. All cases were reviewed by a single uro-pathologist. The prognostic significance of LVI was assessed in
relation to recurrence and stage progression.
Results: The median follow-up period was 53 months. LVI was histologically confirmed in 30 patients (25.9%). There
were no significant differences of clinical features between the patients with and without LVI. In T1 patients,
univariate analysis demonstrated that LVI positivity was associated with stage progression (p = 0.003), but not with
tumor recurrence (p = 0.192). Multivariate analysis confirmed that LVI was independently associated with stage
progression (p = 0.006, hazard ratio = 4.00). In 85 patients who received BCG instillation, LVI was independently
associated with both tumor recurrence and stage progression (p = 0.036 and 0.024, hazard ratio = 2.19 and 3.76).
Conclusions: LVI is a strong indicator of an increased risk of recurrence and progression in BCG-treated patients
with T1 NMIBC. This information might assist clinicians to develop appropriate management and counseling
strategies for these patients.
Keywords: Urinary bladder neoplasms, Carcinoma, Transitional cell, Lymphatic metastasis, Recurrence, Disease
progression
Background
The optimum management and therapeutic strategy for
T1 non-muscle invasive bladder cancer (NMIBC) are
still being debated. As T1 NMIBC has a higher risk of
recurrence and higher progression rate, current guide-
lines recommend adjuvant therapy with bacillus
Calmette-Guérin (BCG) after transurethral resection of
bladder tumor (TURBT) [1]. However, recurrence affects
about half of all patients with T1 NMIBC who receive
BCG therapy and 17 %–23 % show progression to
muscle invasive tumors [2, 3]. Patients with a very high
risk of recurrence and stage progression should receive
more aggressive therapy such as immediate total cystec-
tomy [4]. The clinical outcome of immediate cystectomy
for T1 NMIBC is good, with the 10-year disease-specific
survival rate being approximately 80 % [5, 6], but not all
T1 patients need radical surgery, which has a relatively
high morbidity rate and reduces the quality of life [7].
One of the major issues regarding management of T1
NMIBC is the lack of appropriate tools for identifying
patients with a very high risk of stage progression. Vari-
ous prognostic factors that predict a poor outcome of
* Correspondence: eiji-k@kb3.so-net.ne.jp
1Department of Urology, Keio University School of Medicine, 35
Shinanomachi, Shinjuku-ku, Tokyo 160-0016, Japan
Full list of author information is available at the end of the article
© 2016 Fukumoto et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fukumoto et al. BMC Urology  (2016) 16:5 
DOI 10.1186/s12894-016-0122-1
Ta/T1 NMIBC have been reported, including the sex [3],
age [8, 9], tumor diameter [10], multifocality [8, 10],
concomitant carcinoma in situ (CIS) [10, 11], CIS in the
prostatic urethra [3], histological grade [8], and molecu-
lar grade determined by fluorescence in situ
hybridization [12]. Lymphovascular invasion (LVI) is
considered to be the most important step in the initi-
ation of tumor dissemination/metastasis, and it has been
identified as a strong indicator of a poor prognosis for
various cancers, including carcinoma of the lung [13],
breast [14], colon [15], kidney [16], and prostate [17], as
well as urothelial carcinoma of the upper urinary tract
[18, 19]. In patients with clinical stage I nonseminoma-
tous testicular tumors, information on LVI status was re-
ported to be important for making a decision about
whether or not to provide adjuvant chemotherapy [20].
In patients with muscle invasive bladder cancer treated
by total cystectomy, LVI is a strong indicator of poor
survival, since the 10-year cancer-specific survival rate is
31.0 %–39.3 % for LVI-positive patients versus 72.0 %–
73.6 % for LVI-negative patients [21, 22]. A few investi-
gators have evaluated the influence of LVI in TURBT
specimens of NMIBC patients, but conflicting results
have been reported [23–26]. Therefore, we investigated
the association of LVI status reviewed by a dedicated
uro-pathologist with clinical background factors in T1
NMIBC patients and evaluated whether LVI was useful
for identifying a higher risk of stage progression.
Methods
Patients
A total of 662 patients with newly diagnosed NMIBC
were treated from January 1994 to December 2013 at
Keio University Hospital and 165 patients had T1
NMIBC (Fig. 1). Fifteen patients who received TURBT
at other institutions were excluded. Patients with pure
non-urothelial carcinoma (e.g., squamous cell carcinoma
or adenocarcinoma), a history of upper tract urothelial
carcinoma, and follow-up for less than 6 months were
also excluded (4, 22, and 4 patients, respectively). Fur-
thermore, we excluded 4 patients who had undergone
total cystectomy without confirmation of progression.
Two of them had received immediate total cystectomy,
which meant that it was performed soon after TURBT
without further intravesical therapy. The other 2 patients
had received early total cystectomy, which was per-
formed after recurrence but before stage progression. Fi-
nally, 116 subjects were included in this analysis, among
whom 85 had received instillation of BCG after TURBT.
TURBT, Newly diagnosed 
NMIBC (n = 662)
Newly diagnosed T1 NMIBC 
(n = 165)
Enrollment (n = 116)
Excluded
History of TURBT at other institutions (n = 15)
Pure non-urothelial carcinoma histology (n = 4)
History of upper tract urothelial carcinoma (n = 22)
Less than 6 months of follow-up period (n = 4)
Immediate total cystectomy (n = 2)
Early total cystectomy (n = 2)
Fig. 1 Flow diagram of the study population
Fig. 2 LVI (arrowhead) in a tumor specimen. Hematoxylin and eosin
staining, × 400
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Evaluation of resected specimens
All specimens were reviewed by a dedicated uro-
pathologist who was unaware of the clinical outcome.
Based on examination of hematoxylin and eosin stained
sections, LVI was considered to be present when tumor
cells were unequivocally noted within or attached to the
walls of a vascular or lymphatic space (Fig. 2). Multiple
serial sections were viewed and immunohistochemical
markers for lymphatic channels (D2-40) and endothelial
cells (CD31/34) were used in equivocal cases.
Treatment
Intravesical BCG therapy was generally performed for
intermediate or high risk NMIBC according to the
current clinical guidelines [1]. However, the attending
physician and/or patient sometimes decided against
treatment with BCG because of side effects. Instillation
of BCG was begun 4 to 5 weeks after TURBT and was
continued at weekly intervals for 6 to 8 weeks at a dose
of 80 mg (Tokyo 172 strain) or 81 mg (Connaught
strain). Patients were followed postoperatively with
cystoscopy and urinary cytology every 3 months for 2
years, every 6 months for the next 3 years, and annually
thereafter. Excretory urography and/or computed tom-
ography were performed to evaluate the upper urinary
tract every year for 5 years after treatment.
Endpoints
We defined tumor recurrence as any evidence of disease
on follow-up evaluation, while progression was defined
as muscle invasion or metastasis. Recurrence-free sur-
vival time was calculated as the interval between TURBT
and the date of tumor recurrence, while progression-free
survival was determined from the date of TURBT to
progression. Cancer-specific survival and overall survival
were based on death from bladder cancer and death
from any cause, respectively.
Statistical analysis
Variables were compared between different groups by
using the χ2 test. Recurrence-and progression-free sur-
vival rates were estimated by the Kaplan-Meier method.
Table 1 Clinicopathological characteristics of 116 patients stratified according to LVI status
Characteristic Total LVI positive LVI negative p value
No. of patients 116 30 86
Age 0.073
<70 years 55 (47.4 %) 10 (33.3 %) 45 (52.3 %)
≥70 years 61 (52.6 %) 20 (66.7 %) 41 (47.7 %)
Sex 0.256
Male 98 (84.5 %) 27 (90.0 %) 71 (82.6 %)
Female 18 (15.5 %) 3 (10.0 %) 15 (17.4 %)
Tumor grade 0.115
G1/2 7 (6.0 %) 0 (0.0%) 7 (8.1 %)
G3 109 (94.0 %) 30 (100.0%) 79 (91.9 %)
Concomitant CIS 0.247
Positive 26 (22.4 %) 9 (30.0 %) 17 (19.8 %)
Negative 90 (77.6 %) 21 (70.0 %) 69 (80.2 %)
Multifocality 0.638
Multiple 85 (73.3 %) 21 (70.0 %) 64 (74.4 %)
Solitary 31 (26.7 %) 9 (30.0 %) 22 (25.6 %)
BCG instillation 0.334
Yes 85 (73.3 %) 24 (80.0 %) 61 (70.9 %)
No 31 (26.7 %) 6 (20.0 %) 25 (29.1 %)
Intravesical chemotherapy 0.601
Yes 16 (13.8 %) 4 (13.3 %) 12 (14.0 %)
No 100 (86.2 %) 26 (86.7%) 74 (86.0 %)
History of Ta NMIBC 0.418
Recurrence 7 (6.0 %) 1 (3.3 %) 6 (7.0 %)
Primary 109 (94.0 %) 29 (96.7 %) 80 (93.0 %)
LVI Lymphovascular invasion, CIS Carcinoma in situ, BCG Bacillus Calmette-Guérin, NMIBC Non-muscle invasive bladder cancer
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Survival curves were compared with the log-rank test.
Univariate and multivariate analyses of tumor recurrence
and stage progression were done using the Cox propor-
tional hazards model with stepwise forward regression.
The independent variables included in survival analysis
were patient age (<70 vs. ≥70 years), sex, tumor grade
(G1/2 vs. G3), concomitant CIS, multifocality, intravesi-
cal BCG therapy, intravesical chemotherapy, a history of
Ta NMIBC, and LVI status (positive or negative). Differ-
ences between groups were regarded as significant at P
< 0.05. All analyses were performed with the SPSS v.
21.0 statistical software package (IBM Corp., Somers,
NY).
Ethics and consent
This study was conducted subject to the guidelines of
the Declaration of Helsinki and approved by our ethical
committee. The reference number is 20130101. The eth-
ical committee exempted obtaining informed consent
because our study design was done by a retrospective
fashion. Data were obtained from medical chart and pa-
tient identifying information was anonymized before
analysis.
Results
Clinicopathological characteristics of the 116 patients
The median age of the patients was 70.6 years (range:
40 to 89 years). Men accounted for 84.5% of the pa-
tients (n = 98) and women for 15.5% (n = 18). LVI
was histologically confirmed in 30 patients (25.9%).
Table 1 presents the association between clinicopatho-
logical characteristics and LVI status in the 116 pa-
tients. There were no significant differences of clinical
features between the LVI-positive and LVI-negative
Table 2 Results of univariate and multivariate analyses
Characteristic Recurrence-free survival Progression-free survival
Univariate Multivariate Univariate Multivariate







Tumor grade 0.916 0.289
G1/2
G3






BCG instillation 0.005 0.007 0.953
Yes 0.44 (0.24–0.80)
No
Intravesical chemotherapy 0.007 0.631
Yes
No
History of Ta NMIBC 0.735 0.245
Recurrence
Primary
Lymphovascular invasion 0.192 0.003 0.006
Positive 4.00 (1.49–10.75)
Negative
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patients. During the median follow-up period of 53
months (range: 6–239 months), 47 of 116 patients
(40.5%) experienced recurrence and 16 patients
(13.8%) showed stage progression. Of the 16 patients
with stage progressions, one had distant metastasis.
Fourteen patients died (12.1%) and 7 patients (6.0%)
died of their disease.
Predictors of recurrence and stage progression in all
patients
Univariate and multivariate analyses were performed to
determine the predictors of tumor recurrence and stage
progression (Table 2). Recurrence was noted in 16 pa-
tients (53.3%) from the LVI-positive group and 31 pa-
tients (36.0%) from the LVI-negative group. Treatment
with BCG (p = 0.005) and intravesical chemotherapy (p
= 0.007) had a significant influence on tumor recurrence
according to univariate analysis. Multivariate Cox regres-
sion analysis showed that BCG therapy was an inde-
pendent determinant of a lower risk of tumor
recurrence (p = 0.007, hazard ratio (HR) = 0.44).
Nine patients (30.0%) with LVI demonstrated stage
progression, as did 7 patients (8.1%) without LVI.
Kaplan-Meier analysis showed that patients in the LVI-
positive group had a higher risk of stage progression,
with the 5-year progression-free survival rate being
61.8% in LVI-positive patients and 90.4% in LVI-negative
patients (p = 0.003). Multivariate analysis demonstrated
that LVI had an independent influence on progression-
free survival (p = 0.006, HR = 4.00).
Predictors of recurrence and stage progression in
patients treated with BCG
We performed a subgroup analysis of the 85 patients
who received BCG therapy. Their clinicopathological
characteristics are listed in Table 3. There were no sig-
nificant differences of clinical features between the LVI-
positive and LVI-negative patients. We investigated
whether LVI had a prognostic impact on tumor recur-
rence and stage progression (Table 4). Among the 85 pa-
tients, LVI was confirmed in 24 patients (28.2%). In the
LVI-positive group, 13 patients (54.2%) experienced re-
currence and 7 patients (29.2%) showed stage progres-
sion, while the corresponding numbers in the LVI-
negative group were 16 (26.2%) and 5 (8.2%), respect-
ively. Kaplan-Meier analysis revealed that the 5-year
recurrence-free and progression-free survival rates of
LVI-positive patients were 39.5% and 65.9%, respectively,
which were significantly lower than those of LVI-
negative patients (71.2% and 90.8%, p = 0.032 and 0.015,
respectively; Figs. 3 and 4). Multivariate analysis con-
firmed that LVI had an independent influence on
recurrence-free and progression-free survival in T1
NMIBC patients treated with BCG (p = 0.036 and 0.024,
HR = 2.19 and 3.76, respectively).
Association of LVI status with cancer-specific survival and
overall survival
Among 16 patients with stage progression, 7 underwent
total cystectomy, 3 were treated with radiation therapy,
and 1 received systemic chemotherapy. Five patients re-
ceived no treatment at their request. The 5-year cancer-
specific survival rate of LVI-negative patients was 96.3%,
which was marginally higher than that of LVI-positive
patients (79.8%, p = 0.07). The 5-year overall survival
rate of LVI-negative patients was 89.4%, which was not
significantly different from that of LVI-positive patients
(71.8%, p = 0.185). In the patients treated with BCG, LVI
status was not associated with either cancer-specific sur-
vival or overall survival (p = 0.143 and 0.235,
respectively).
Discussion
Our study of 116 patients with T1 NMIBC revealed that
LVI was significantly associated with stage progression
after TURBT. In addition, we confirmed that LVI posi-
tivity was an independent risk factor for tumor recur-
rence and progression in T1 NMIBC patients treated
with intravesical BCG instillation. To the best of our
knowledge, this is the first report that LVI in TURBT
specimens is significantly associated with recurrence and
Table 3 Clinicopathological characteristics of 85 BCG-treated
patients stratified according to LVI status
Characteristic Total LVI positive LVI negative P value
No. of patients 85 24 61
Age 0.074
<70 years 45 (52.9%) 9 (37.5%) 36 (59.0%)
≥70 years 40 (47.1%) 15 (62.5%) 25 (41.0%)
Sex 0.174
Male 71 (83.5%) 22 (91.7%) 49 (80.3%)
Female 14 (16.5%) 2 (8.3%) 12 (19.7%)
Tumor grade 0.258
G1/2 4 (4.7%) 0 (0.0%) 4 (6.6%)
G3 81 (95.3%) 24 (100.0%) 57 (93.4%)
Concomitant CIS 0.969
Positive 21 (24.7%) 6 (25.0%) 15 (24.6%)
Negative 64 (75.3%) 18 (75.0%) 46 (75.4%)
Multifocality 0.905
Multiple 61 (71.8%) 17 (70.8%) 44 (72.1%)
Solitary 24 (28.2%) 7 (29.2%) 17 (27.9%)
History of Ta NMIBC 0.563
Recurrence 5 (5.9%) 1 (4.2%) 4 (6.6%)
Primary 80 (94.1%) 23 (95.8%) 57 (93.4%)
Fukumoto et al. BMC Urology  (2016) 16:5 Page 5 of 9
stage progression of T1 NMIBC after treatment with
BCG.
T1 NMIBC has a high potential for recurrence, and
some patients experience stage progression that requires
more aggressive therapy such as total cystectomy. There-
fore, it is critical to identify the subset of T1 NMIBC pa-
tients whose tumors are highly malignant and have the
potential to progress to muscle invasive disease. Various
biological markers (such as p16, pRb, p53, MIB-1, and
HSP90) have been studied for identifying aggressive T1
tumors [27–29], but these are relatively expensive and
require additional procedures for histopathological ana-
lysis. In contrast, LVI can easily be investigated during
standard histopathological evaluation.
Several investigators have already investigated whether
the LVI status of TURBT specimens was a prognostic
factor in patients with NMIBC. Lopez et al. [23] re-
ported an LVI positivity rate of 10% (17/170 T1 NMIBC
patients) in their series and found that the LVI status
was associated with overall survival. However, their pa-
tients were collected from 1983 to 1990 and were
treated by adjuvant intravesical chemotherapy (mitomy-
cin C or Adriamycin). Also, they did not determine the
predictive value of LVI status for recurrence or stage
progression by multivariate analysis. Andius et al. [24]
analyzed 121 patients with T1 NMIBC, and found an as-
sociation between LVI status and stage progression as
well as cancer-specific survival. The same pathologist
reviewed all histopathological material, as was done in
our study, and LVI was confirmed in 12 patients (10%).
In multivariate analysis, LVI was associated with both
stage progression and cancer-specific survival. However,
TURBT was performed between 1987 and 1988 in their
study, and only one patient received adjuvant BCG in-
stillation. Conflicting results with regard to the predict-
ive value of LVI status for a poor clinical outcome have
been reported in the era when BCG was established as
standard adjuvant therapy for T1 NMIBC. Cho et al.
[25] reviewed 118 patients with T1 NMIBC who under-
went TURBT between 2001 and 2007, and evaluated the
impact of LVI on tumor recurrence, stage progression,
and metastasis. Two independent uro-pathologists
reviewed the slides and found 33 LVI-positive patients
(28%). Their multivariate analysis showed that LVI was
significantly associated with tumor recurrence and stage
progression, but the study population had a low rate of
BCG instillation (22.9%). Branchereau et al. [26] assessed
the prognostic value of LVI in 108 patients with high
Table 4 Results of univariate and multivariate analyses in patients treated with BCG after TURBT
Characteristic Recurrence-free survival Progression-free survival
Univariate Multivariate Univariate Multivariate







Tumor grade 0.593 0.424
G1/2
G3






History of Ta NMIBC 0.694 0.079
Recurrence
Primary
Lymphovascular invasion 0.032 0.036 0.015 0.024
Positive 2.19 (1.05–4.55) 3.76 (1.19–11.90)
Negative
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Fig. 3 Recurrence-free survival rate according to LVI status in patients treated with BCG
Fig. 4 Progression-free survival rate according to LVI status in patients treated with BCG
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grade T1 NMIBC, including 60 patients (57%) who
received adjuvant BCG therapy after TURBT. They
reported that LVI was not associated with tumor re-
currence, stage progression, cancer-specific survival,
or overall survival. In contrast, we clearly demon-
strated that LVI status could independently predict
recurrence and stage progression in T1 NMIBC pa-
tients receiving BCG therapy and that evaluation of
LVI in tumor specimens could provide useful informa-
tion planning the appropriate management strategy and
patient counseling.
In the present series, the LVI status was only de-
scribed for 54 patients (46.6%) in the original path-
ology reports. Among the remaining 62 patients
(53.4%), a further 13 LVI-positive cases were found
after review by our uro-pathologist. At our institution,
some pathologists routinely evaluate LVI, while others
do not mention the LVI status. One of the reasons
for this difference might be that the predictive role of
LVI status in TURBT specimens has not been estab-
lished clinically, especially for T1 NMIBC. Berman
et al. evaluated 2802 patients with muscle invasive
bladder tumors treated by total cystectomy using the
Ontario cancer registry dataset and found that path-
ology reports failed to address LVI status in 25%, with
LVI reporting rates being significantly higher at the
high volume centers for total cystectomy [30]. They
concluded that assessment of LVI status in a stan-
dardized manner across all bladder specimens by pa-
thologists is essential to improve the diagnostic and
therapeutic strategies for this cancer. Our findings in-
dicated that urologists and pathologists should share
information concerning the prognostic significance of
LVI, even in T1 NMIBC, emphasizing the importance
of assessing and reporting LVI.
The present study had several limitations, including
a small number of patients initially diagnosed with T1
bladder cancer and the long study period of 20 years,
which was likely to have led to the low repeat
TURBT rate (18.1%). Furthermore, we did not rou-
tinely perform maintenance BCG therapy in patients
initially diagnosed with T1 bladder cancer and treat-
ment after TURBT was not uniform. While 85 pa-
tients (73.3%) were treated with BCG, others received
intravesical chemotherapy (13.8%) or no adjuvant
therapy (12.9%). Therefore, we performed a subgroup
analysis of the patients who received BCG therapy,
which revealed that LVI status was an independent
predictor of recurrence and stage progression in these
patients. Since this study was retrospective, we cannot
exclude the possibility of unknown biases, but we be-
lieve that consistent pathological data was obtained
because the same uro-pathologist reviewed all of the
specimens.
Conclusions
The presence of LVI is a strong risk factor for tumor re-
currence and stage progression in T1 NMIBC patients
treated with BCG. This finding might assist in the devel-
opment of appropriate management and counseling
strategies for T1 NMIBC patients. Urologists and pa-
thologists should be aware of the prognostic significance
of LVI in T1 disease.
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